[
    "{\"step_by_step_thinking\": \"Based on the information provided, istiratumab (MM-141) was tested in a randomized, double-blind, placebo-controlled phase II study for patients with previously untreated metastatic pancreatic cancer. The study aimed to determine whether istiratumab, an IGF-1R- and ErbB3-bispecific antibody, can enhance the efficacy of standard of care chemotherapy in patients with high IGF-1 serum levels. The study found that istiratumab failed to improve the efficacy of standard of care chemotherapy in this patient setting. Therefore, the answer is B. no.\", \"answer_choice\": \"B\"}"
]